We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sienna Biopharmaceuticals’ acne candidate SNA-001 has comprehensively failed two phase 3 trials. The addition of the silver particle treatment to laser light therapy failed to improve outcomes against three key endpoints.....